SEC Form 4 · accession 0001209191-16-126032
ANTARES PHARMA, INC. · ATRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James E Fickenscher
Officer — Senior Vice President & CFO
Period of report
Jun 2, 2016
Accepted (ET)
Jun 6, 2016 · 5:19 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001016169
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 2, 2016 | A | 121,050 | $1.12 | A | 391,266 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F2,F3 | $1.12 | Jun 2, 2016 | A | 257,900 | A | — | Jun 2, 2026 | Common Stock | 257,900 | 257,900 | D |
Explanation of responses
- F1Represents grant of restricted stock units made under the 2008 Equity Compensation Plan. The shares vest in three equal annual installments.
- F2Represents grant of options to purchase shares of common stock, par value $0.01 per share, issued under the Antares Pharma, Inc. 2008 Equity Compensation Plan.
- F3The options vest in equal quarterly installments over three years from the date of grant.